BOB Capital Markets Ltd.
Q2FY25 results were below our estimates on all fronts; however, ALPM expects H2 to be better than H1FY25 driven by healthy product mix
Alembic Pharmaceuticals Ltd. has gained 27.11% in the last 3 Months
More from Alembic Pharmaceuticals Ltd.
Recommended